Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hualan Genetic to Develop Three Harbour BioMed Antibodies in Return for China Rights

publication date: Sep 11, 2020

Hualan Genetic Engineering agreed to develop three Harbour BioMed novel monoclonal and bispecific antibodies in return for China marketing rights to the candidates. Hualan Genetic, previously a company focused on biosimilars, will be responsible for preclinical and process development. It will also make an $8.75 million upfront payment, plus pay royalties. Harbour BioMed, which is headquartered in the US with R&D facilities in China, will retain the rights to the antibodies in the rest of the world. Both companies will collaborate on clinical developments and drug manufacturing. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital